The US FDA has approved a combination of sulopenem etzadroxil and probenecid for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited or no alternative oral antibacterial treatment options. This combination therapy is particularly indicated for uUTIs caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis .
Sulopenum etzadroxil is a prodrug that converts into sulopenem, a penem antibacterial drug, while probenecid is a renal tubular transport inhibitor that reduces the renal clearance of sulopenem Clinical evidence In two clinical trials, the combination of sulopenem etzadroxil and probenecid demonstrated superiority over ciprofloxacin in uUTI patients with fluoroquinolone-resistant infections, as well as over a combination of amoxicillin and clavulanate potassium in uUTI patients. Administration – Oral Limitations of use The sulopenem…
